Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

106.34 -2.36 (-2.17%)
Official Closing Price Updated: 7:00 PM EDT, Oct 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,444,910
Open 109.08
Bid (Size) 106.00 (3)
Ask (Size) 106.25 (13)
Prev. Close 108.70
Today's Range 106.18 - 109.17
52wk Range 99.80 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success... 
Via Benzinga
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
-6.09%
-6.09%
1 Month
-8.03%
-8.03%
3 Month
-15.40%
-15.40%
6 Month
-16.23%
-16.23%
1 Year
+2.89%
+2.89%

More News

Read More
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Via Benzinga
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
Via Benzinga
Is NYSE:MRK a Good Fit for Dividend Investing?
Via Chartmill
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
From Merck & Co., Inc.
Via Business Wire
Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
From Merck & Co., Inc.
Via Business Wire
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
Via Investor's Business Daily
Exposures Product Safety
Up 700% This Year, Is It Too Late to Invest in This Stock?
Via The Motley Fool
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Via MarketBeat
2 Incredibly Cheap Big Pharma Stocks to Buy Now
Via The Motley Fool
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Via Benzinga
Topics Stocks
Exposures US Equities
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
Via Benzinga
NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
From Merck & Co., Inc.
Via Business Wire
Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients
Via Benzinga
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
Via The Motley Fool
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.